Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207670 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
A Phase 2 study of Non-Hodgkin Lymphoma, sponsored by Genentech.
- Active
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT05207670 is a Phase 2 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Genentech. The registered enrollment target is 320 participants, above the 149-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (115% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT05207670, a Phase 2 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG Mosunetuzumab (Cohorts A-C)
- DRUG Mosunetuzumab (Cohorts D-E)
Study Locations (20)
Florida
- SCRI Florida Cancer Specialists South - Fort Myers
- Mayo Clinic Jacksonville - PPDS - Jacksonville
- Cancer Specialists of North Florida - Jacksonville - Jacksonville
- Florida Cancer Specialists - NORTH - SCRI - PPDS - St. Petersburg
- Florida Cancer Specialists - EAST - SCRI - PPDS - West Palm Beach
Alabama
- Infirmary Cancer Care - Mobile
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Arizona
- Mayo Clinic Arizona - Phoenix
California
- City of Hope - Duarte
Colorado
- Rocky Mountain Cancer Centers (Aurora) - USOR - Aurora
Delaware
- Medical Oncology Hematology Consultants - Newark
Iowa
- Mission Blood and Cancer - MercyOne Cancer Center - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05207670
The ClinicalTrials.gov registry entry for NCT05207670 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (115% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Tocilizumab is the first listed.
NCT05207670 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT05207670 about?
NCT05207670 is a clinical study titled "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies". This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).
What is the current status of trial NCT05207670?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2022-02-01. Estimated completion is 2028-07-31.
What conditions does trial NCT05207670 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05207670?
The interventions under investigation include: Tocilizumab (DRUG), Mosunetuzumab (Cohorts A-C) (DRUG), Mosunetuzumab (Cohorts D-E) (DRUG).
Who is sponsoring clinical trial NCT05207670?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05207670 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.